These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 33523015)

  • 1. Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls.
    Mendell JR; Khan N; Sha N; Eliopoulos H; McDonald CM; Goemans N; Mercuri E; Lowes LP; Alfano LN;
    J Neuromuscul Dis; 2021; 8(4):469-479. PubMed ID: 33523015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.
    Mendell JR; Goemans N; Lowes LP; Alfano LN; Berry K; Shao J; Kaye EM; Mercuri E;
    Ann Neurol; 2016 Feb; 79(2):257-71. PubMed ID: 26573217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial.
    McDonald CM; Shieh PB; Abdel-Hamid HZ; Connolly AM; Ciafaloni E; Wagner KR; Goemans N; Mercuri E; Khan N; Koenig E; Malhotra J; Zhang W; Han B; Mendell JR;
    J Neuromuscul Dis; 2021; 8(6):989-1001. PubMed ID: 34120909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy.
    Khan N; Eliopoulos H; Han L; Kinane TB; Lowes LP; Mendell JR; Gordish-Dressman H; Henricson EK; McDonald CM;
    J Neuromuscul Dis; 2019; 6(2):213-225. PubMed ID: 30856119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy.
    Alfano LN; Charleston JS; Connolly AM; Cripe L; Donoghue C; Dracker R; Dworzak J; Eliopoulos H; Frank DE; Lewis S; Lucas K; Lynch J; Milici AJ; Flynt A; Naughton E; Rodino-Klapac LR; Sahenk Z; Schnell FJ; Young GD; Mendell JR; Lowes LP
    Medicine (Baltimore); 2019 Jun; 98(26):e15858. PubMed ID: 31261494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production.
    Charleston JS; Schnell FJ; Dworzak J; Donoghue C; Lewis S; Chen L; Young GD; Milici AJ; Voss J; DeAlwis U; Wentworth B; Rodino-Klapac LR; Sahenk Z; Frank D; Mendell JR
    Neurology; 2018 Jun; 90(24):e2146-e2154. PubMed ID: 29752304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment.
    Mitelman O; Abdel-Hamid HZ; Byrne BJ; Connolly AM; Heydemann P; Proud C; Shieh PB; Wagner KR; Dugar A; Santra S; Signorovitch J; Goemans N; ; McDonald CM; ; Mercuri E; ; Mendell JR
    J Neuromuscul Dis; 2022; 9(1):39-52. PubMed ID: 34420980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eteplirsen in the treatment of Duchenne muscular dystrophy.
    Lim KR; Maruyama R; Yokota T
    Drug Des Devel Ther; 2017; 11():533-545. PubMed ID: 28280301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eteplirsen for the treatment of Duchenne muscular dystrophy.
    Mendell JR; Rodino-Klapac LR; Sahenk Z; Roush K; Bird L; Lowes LP; Alfano L; Gomez AM; Lewis S; Kota J; Malik V; Shontz K; Walker CM; Flanigan KM; Corridore M; Kean JR; Allen HD; Shilling C; Melia KR; Sazani P; Saoud JB; Kaye EM;
    Ann Neurol; 2013 Nov; 74(5):637-47. PubMed ID: 23907995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Pulmonary Function in Duchenne Muscular Dystrophy: Comparison of Eteplirsen-Treated Patients to Natural History.
    Kinane TB; Mayer OH; Duda PW; Lowes LP; Moody SL; Mendell JR
    J Neuromuscul Dis; 2018; 5(1):47-58. PubMed ID: 29278896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.
    Shimizu-Motohashi Y; Murakami T; Kimura E; Komaki H; Watanabe N
    Orphanet J Rare Dis; 2018 Jun; 13(1):93. PubMed ID: 29907124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6-48 months with Duchenne muscular dystrophy amenable to exon 51 skipping.
    Mercuri E; Seferian AM; Servais L; Deconinck N; Stevenson H; Ni X; Zhang W; East L; Yonren S; Muntoni F;
    Neuromuscul Disord; 2023 Jun; 33(6):476-483. PubMed ID: 37207382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls.
    Iff J; Done N; Tuttle E; Zhong Y; Wei F; Darras BT; McDonald CM; Mercuri E; Muntoni F
    Muscle Nerve; 2024 Jul; 70(1):60-70. PubMed ID: 38482981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eteplirsen: First Global Approval.
    Syed YY
    Drugs; 2016 Nov; 76(17):1699-1704. PubMed ID: 27807823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eteplirsen for paediatric patients with Duchenne muscular dystrophy: A pooled-analysis.
    Randeree L; Eslick GD
    J Clin Neurosci; 2018 Mar; 49():1-6. PubMed ID: 29254734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update.
    Sheikh O; Yokota T
    Arch Toxicol; 2022 Jan; 96(1):1-9. PubMed ID: 34797383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial.
    Servais L; Mercuri E; Straub V; Guglieri M; Seferian AM; Scoto M; Leone D; Koenig E; Khan N; Dugar A; Wang X; Han B; Wang D; Muntoni F;
    Nucleic Acid Ther; 2022 Feb; 32(1):29-39. PubMed ID: 34788571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy.
    Iff J; Gerrits C; Zhong Y; Tuttle E; Birk E; Zheng Y; Paul X; Henricson EK; McDonald CM;
    Muscle Nerve; 2022 Sep; 66(3):262-269. PubMed ID: 35715998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eteplirsen Treatment for Duchenne Muscular Dystrophy: A Qualitative Patient Experience Study.
    Iff J; Carmichael C; McKee S; Sehinovych I; McNeill C; Tesi-Rocha C; Henricson E; Muntoni F; Kitchen H
    Adv Ther; 2024 Jul; ():. PubMed ID: 38958840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.